|
1
|
Hopper AD, Jalal M and Munir A: Recent
advances in the diagnosis and management of pancreatic
neuroendocrine tumours. Frontline Gastroenterol. 10:269–274.
2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dasari A, Shen C, Halperin D, Zhao B, Zhou
S, Xu Y, Shih T and Yao JC: Trends in the incidence, prevalence,
and survival outcomes in patients with neuroendocrine tumors in the
United States. JAMA Oncol. 3:1335–1342. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Dumlu EG, Karakoc D and Özdemir A:
Nonfunctional pancreatic neuroendocrine tumors: Advances in
diagnosis, management, and controversies. Int Surg. 100:1089–1097.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Scarpa A, Chang DK, Nones K, Corbo V,
Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, et
al: Whole-genome landscape of pancreatic neuroendocrine tumours.
Nature. 543:65–71. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Raj N, Shah R, Stadler Z, Mukherjee S,
Chou J, Untch B, Li J, Kelly V, Saltz LB, Mandelker D, et al:
Real-time genomic characterization of metastatic pancreatic
neuroendocrine tumors has prognostic implications and identifies
potential germline actionability. JCO Precis Oncol 2018:
PO.17.00267, 2018.
|
|
6
|
Ji S, Yang W, Liu J, Zhao J, Chen L, Ni Q,
Long J and Yu X: High throughput gene sequencing reveals altered
landscape in DNA damage responses and chromatin remodeling in
sporadic pancreatic neuroendocrine tumors. Pancreatology.
18:318–327. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhang J, Francois R, Iyer R, Seshadri M,
Zajac-Kaye M and Hochwald SN: Current understanding of the
molecular biology of pancreatic neuroendocrine tumors. J Natl
Cancer Inst. 105:1005–1017. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Batukbhai BDO and De Jesus-Acosta A: The
molecular and clinical landscape of pancreatic neuroendocrine
tumors. Pancreas. 48:9–21. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chan CS, Laddha SV, Lewis PW, Koletsky MS,
Robzyk K, Da Silva E, Torres PJ, Untch BR, Li J, Bose P, et al:
ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a
distinct alpha-cell signature subgroup. Nat Commun.
9(4158)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pipinikas CP, Berner AM, Sposito T and
Thirlwell C: The evolving (epi)genetic landscape of pancreatic
neuroendocrine tumours. Endocr Relat Cancer. 26:R519–R544.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
<gutjnl-2018-insulinomas and
non-functional PNETs.pdf>.
|
|
12
|
Cai H, Jing C, Chang X, Ding D, Han T,
Yang J, Lu Z, Hu X, Liu Z, Wang J, et al: Mutational landscape of
gastric cancer and clinical application of genomic profiling based
on target next-generation sequencing. J Transl Med.
17(189)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Rindi G, Bordi C, La Rosa S, Solcia E and
Fave GD: Gruppo Italiano Patologi Apparato Digerente (GIPAD);
Società Italiana di Anatomia Patologica e Citopatologia
Diagnostica/International Academy of Pathology, Italian division
(SIAPEC/IAP). Gastroenteropancreatic (neuro)endocrine neoplasms:
The histology report. Dig Liver Dis. 43 (Suppl 4):S356–S360.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Halfdanarson TR, Strosberg JR, Tang L,
Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L,
Eads J, Hope TA, et al: The North American neuroendocrine tumor
society consensus guidelines for surveillance and medical
management of pancreatic neuroendocrine tumors. Pancreas.
49:863–881. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Clavé S, Gimeno J, Muñoz-Mármol AM, Vidal
J, Reguart N, Carcereny E, Pijuan L, Menéndez S, Taus Á, Mate JL,
et al: ROS1 copy number alterations are frequent in non-small cell
lung cancer. Oncotarget. 7:8019–8028. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen S, Zhou Y, Chen Y and Gu J: fastp: An
ultra-fast all-in-one FASTQ preprocessor. Bioinformatics.
34:i884–i890. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li H and Durbin R: Fast and accurate
long-read alignment with burrows-wheeler transform. Bioinformatics.
26:589–595. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li H, Handsaker B, Wysoker A, Fennell T,
Ruan J, Homer N, Marth G, Abecasis G and Durbin R: 1000 Genome
Project Data Processing Subgroup. The sequence alignment/map format
and SAMtools. Bioinformatics. 25:2078–2079. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A MapReduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
García-Alcalde F, Okonechnikov K,
Carbonell J, Cruz LM, Götz S, Tarazona S, Dopazo J, Meyer TF and
Conesa A: Qualimap: Evaluating next-generation sequencing alignment
data. Bioinformatics. 28:2678–2679. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
1000 Genomes Project Consortium. Auton A,
Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL,
McCarthy S, McVean GA and Abecasis GR: A global reference for human
genetic variation. Nature. 526:68–74. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Adzhubei I, Jordan DM and Sunyaev SR:
Predicting functional effect of human missense mutations using
PolyPhen-2. Curr Protoc Hum Genet Chapter.
7(Unit7.20)2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ng PC and Henikoff S: SIFT: Predicting
amino acid changes that affect protein function. Nucleic Acids Res.
31:3812–3814. 2003.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Schwarz JM, Rödelsperger C, Schuelke M and
Seelow D: MutationTaster evaluates disease-causing potential of
sequence alterations. Nat Methods. 7:575–576. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kircher M, Witten DM, Jain P, O'Roak BJ,
Cooper GM and Shendure J: A general framework for estimating the
relative pathogenicity of human genetic variants. Nat Genet.
46:310–315. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA:
WHO Classification of Tumours Editorial Board. The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hong X, Qiao S, Li F, Wang W, Jiang R, Wu
H, Chen H, Liu L, Peng J, Wang J, et al: Whole-genome sequencing
reveals distinct genetic bases for insulinomas and non-functional
pancreatic neuroendocrine tumours: Leading to a new classification
system. Gut. 69:877–887. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Cancer Genome Atlas Network. Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cancer Genome Atlas Network. Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Beijers HJBH, Stikkelbroeck NML,
Mensenkamp AR, Pfundt R, van der Luijt RB, Timmers HJLM, Hermus
ARMM and Kempers MJE: Germline and somatic mosaicism in a family
with multiple endocrine neoplasia type 1 (MEN1) syndrome. Eur J
Endocrinol. 180:K15–K19. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Matkar S, Thiel A and Hua X: Menin: A
scaffold protein that controls gene expression and cell signaling.
Trends Biochem Sci. 38:394–402. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang Y, Ozawa A, Zaman S, Prasad NB,
Chandrasekharappa SC, Agarwal SK and Marx SJ: The tumor suppressor
protein menin inhibits AKT activation by regulating its cellular
localization. Cancer Res. 71:371–382. 2011.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Fang M, Xia F, Mahalingam M, Virbasius CM,
Wajapeyee N and Green MR: MEN1 is a melanoma tumor suppressor that
preserves genomic integrity by stimulating transcription of genes
that promote homologous recombination-directed DNA repair. Mol Cell
Biol. 33:2635–2647. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lin SY and Elledge SJ: Multiple tumor
suppressor pathways negatively regulate telomerase. Cell.
113:881–889. 2003.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lawrence B, Blenkiron C, Parker K, Tsai P,
Fitzgerald S, Shields P, Robb T, Yeong ML, Kramer N, James S, et
al: Recurrent loss of heterozygosity correlates with clinical
outcome in pancreatic neuroendocrine cancer. NPJ Genom Med.
3(18)2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Leoncini E, Carioli G, La Vecchia C,
Boccia S and Rindi G: Risk factors for neuroendocrine neoplasms: A
systematic review and meta-analysis. Ann Oncol. 27:68–81.
2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ben Q, Zhong J, Fei J, Chen H, Yv L, Tan J
and Yuan Y: Risk factors for sporadic pancreatic neuroendocrine
tumors: A case-control study. Sci Rep. 6(36073)2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Gallo M, Ruggeri RM, Muscogiuri G, Pizza
G, Faggiano A and Colao A: NIKE Group. Diabetes and pancreatic
neuroendocrine tumours: Which interplays, if any? Cancer Treat Rev.
67:1–9. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Fan Z, Gong Y, Huang Q, Yang C, Cheng H,
Jin K, Fan K, Ni Q, Yu X, Luo G and Liu C: Diabetes is associated
with the metastasis of pancreatic neuroendocrine tumors. Pancreas.
49:751–756. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Maxwell KN and Domchek SM: Cancer
treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin
Oncol. 9:520–528. 2012.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Sharma MB, Carus A, Sunde L,
Hamilton-Dutoit S and Ladekarl M: BRCA-associated
pancreatico-biliary neoplasms: Four cases illustrating the emerging
clinical impact of genotyping. Acta Oncol. 55:377–381.
2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lin AL and Gutmann DH: Advances in the
treatment of neurofibromatosis-associated tumours. Nat Rev Clin
Oncol. 10:616–624. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Gutmann DH, Ferner RE, Listernick RH, Korf
BR, Wolters PL and Johnson KJ: Neurofibromatosis type 1. Nat Rev
Dis Primers. 3(17004)2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Frost M, Lines KE and Thakker RV: Current
and emerging therapies for PNETs in patients with or without MEN1.
Nat Rev Endocrinol. 14:216–227. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Perren A, Wiesli P, Schmid S, Montani M,
Schmitt A, Schmid C, Moch H and Komminoth P: Pancreatic endocrine
tumors are a rare manifestation of the neurofibromatosis type 1
phenotype: Molecular analysis of a malignant insulinoma in a NF-1
patient. Am J Surg Pathol. 30:1047–1051. 2006.PubMed/NCBI View Article : Google Scholar
|
